New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 26, 2012
07:17 EDTAEGRAegerion label for Juxtapid looks favorable, says JPMorgan
JPMorgan views the label for Aegerion's Juxtapid as favorable and reiterates an Overweight rating on the stock after the FDA approved the drug. The firm upped its price target for shares to $30 from $28.
News For AEGR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 14, 2015
13:32 EDTAEGRAegerion urged to fire CEO, consider sale, Reuters reports
Subscribe for More Information
13:26 EDTAEGRAegerion jumps 7% after report of investor pressure for sale
Subscribe for More Information
13:25 EDTAEGRAegerion investors calling on company to be sold, Reuters reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use